RxDoctor Payments Data

Jose Ayala, MD

Internal Medicine · Bayamon, PRNPI 1538102264

Payments from drug & device makers

$1,687in general payments, 2019–2025

Across 61 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$688
  • Johnson & Johnson$392
  • GSK$250
  • Merck$123
  • PBG Puerto Rico LLC$88
  • AbbVie$75
  • plus $71 from 3 others

What the payments were for

  • Food & beverage$1,66399%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca29$688
Johnson & Johnson11$392
GSK9$250
Merck2$123
PBG Puerto Rico LLC4$88
AbbVie3$75
Amgen1$27
Novartis1$24
E.r. Squibb & Sons, L.L.C.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,687 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,716
Medicare patients
21
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$131,037
XareltoRivaroxaban96$68,050
Humulin NInsulin Nph Human Isophane676$57,627
SynthroidLevothyroxine Sodium257$27,062
Atorvastatin Calcium1,764$26,988
Wixela InhubFluticasone Propion/Salmeterol100$20,900
Metoprolol Succinate665$15,272
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$14,059
FarxigaDapagliflozin Propanediol19$13,249
Levothyroxine Sodium704$13,046
Losartan Potassium803$11,994
Montelukast Sodium564$11,296
Doxazosin Mesylate389$10,115
Gabapentin765$9,649
Humulin RInsulin Regular, Human124$8,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$392$68,05096 claims
AbbVieSynthroid$75$27,062257 claims
AstraZenecaFarxiga, Brilinta, Symbicort$688$24,18350 claims
GSKTrelegy Ellipta$250$14,05921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →